Page last updated: 2024-11-07

interleukin-1beta (163-171)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

interleukin-1beta (163-171): nonapeptide which has in vivo immunostimulating activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123872
SCHEMBL ID6856783
MeSH IDM0150241

Synonyms (16)

Synonym
NCGC00167209-01
il-1beta (163-171)
106021-96-9
interleukin 1-beta (163-171)
interleukin-1beta (163-171)
l-lysine, n2-(n-(n2-(n-(n-(n-(n-(n2-l-valyl-l-glutaminyl)glycyl)-l-alph-glutamyl)-l-alpha-glutamyl)-l-seryl)-l-asparaginyl)-l-alpha-aspartyl)-
SCHEMBL6856783
A15426
l-lysine,l-valyl-l-glutaminylglycyl-l-a-glutamyl-l-a-glutamyl-l-seryl-l-asparaginyl-l-a-aspartyl-
h-val-gln-gly-glu-glu-ser-asn-asp-lys-oh
val-gln-gly-glu-glu-ser-asn-asp-lys-oh
l-valyl-l-glutaminylglycyl-l-glutamyl-l-glutamyl-l-seryl-l-asparaginyl-l-aspartyl-l-lysine
-interleukin i (163-171), human
HY-113893
CS-0063273
(2s)-6-amino-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-5-amino-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]am

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In contrast, the noninflammatory adjuvant IL-1 beta peptide VQGEESNDK (position 163-171) did not induce any toxic effect in vivo, when administered following the same schedule."( Mechanism of acute toxicity of IL-1 beta in mice.
Boraschi, D; Ghezzi, P; Ghiara, P; Mengozzi, M; Parente, L; Silvestri, S; Solito, E; Tagliabue, A; Van Damme, J; Villa, L,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" The nonapeptide, however, is less effective than hurIL-1 beta and displays a different dose-response relationship, suggesting that the two molecules act through different radioprotective pathways."( Radiation protection and restoration by the synthetic 163-171 nonapeptide of human interleukin 1 beta.
Baschieri, S; Boraschi, D; Doria, G; Frasca, D; Tagliabue, A, 1991
)
0.28
" MK2i or PBS was dosed daily for 14 days subsequent to bleomycin injury, beginning on either Day 7 or Day 14."( Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis.
Cummings, OW; Fisher, A; Gu, H; Lander, C; Mickler, EA; Panitch, A; Sandusky, GE; Vittal, R; Wilkes, DS, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (186)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (8.06)18.7374
1990's46 (24.73)18.2507
2000's48 (25.81)29.6817
2010's59 (31.72)24.3611
2020's18 (9.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.65 (24.57)
Research Supply Index5.28 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (1.56%)5.53%
Reviews5 (2.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.52%)0.25%
Other183 (95.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]